Publications

1. Artymiuk CJ, Basu S, Koganti T, Tandale P, Balan J, Dina MA, Barr Fritcher EG, Wu X, Ashworth T, He R, Viswanatha DS. Clinical Validation of a Targeted Next-Generation Sequencing Panel for Lymphoid Malignancies. J Mol Diagn. 2024 Apr 4 Epub 2024 Apr 04
   View PubMed
2. Brow D, Shike H, Kendrick J, Pettersson L, Mineishi S, Claxton DF, Wirk B, Cioccio J, Greiner RJ, Viswanatha D, Kharfan-Dabaja MA, Li Z, Tyler J, Elrefaei M. Assessment of chimerism by next generation sequencing: A comparison to STR/qPCR methods. Hum Immunol. 2024 Mar 28; 110794 [Epub ahead of print]
   View PubMed
3. Olteanu H, Patnaik M, Koster MJ, Herrick JL, Chen D, He R, Viswanatha D, Warrington KJ, Go RS, Mangaonkar AA, Kourelis T, Hines A, Gibson SE, Peterson JF, Reichard KK. Comprehensive morphologic characterization of bone marrow biopsy findings in a large cohort of patients with VEXAS syndrome: A single-institution longitudinal study of 111 bone marrow samples from 52 patients. Am J Clin Pathol. 2024 Feb 27 [Epub ahead of print]
   View PubMed
4. Baranwal A, Basmaci R, He R, Viswanatha D, Greipp P, Murthy HS, Foran J, Palmer J, Hogan WJ, Litzow MR, Hefazi M, Mangaonkar A, Shah MV, Al-Kali A, Alkhateeb HB. Genetic features and outcomes of allogeneic transplantation in patients with WT1-mutated myeloid neoplasms. Blood Adv. 2024 Feb 13; 8 (3):562-570
   View PubMed
5. Baranwal A, Gurney M, Basmaci R, Katamesh B, He R, Viswanatha DS, Greipp P, Foran J, Badar T, Murthy H, Yi CA, Palmer J, Mangaonkar AA, Patnaik MM, Litzow MR, Hogan WJ, Begna K, Gangat N, Tefferi A, Al-Kali A, Shah MV, Alkhateeb HB. Genetic landscape and clinical outcomes of patients with BCOR mutated myeloid neoplasms. Haematologica. 2024 Feb 1 Epub 2024 Feb 01
   View PubMed
6. Badar T, Nanaa A, Foran JM, Viswanatha D, Al-Kali A, Lasho T, Finke C, Alkhateeb HB, He R, Gangat N, Shah M, Tefferi A, Mangaonkar AA, Litzow MR, Ongie LJ, Chlon T, Ferrer A, Patnaik MM. Clinical and molecular correlates of somatic and germline DDX41 variants in patients and families with myeloid neoplasms. Haematologica. 2023 Nov 01; 108(11):3033-3043.
   View PubMed
7. Yuan J, Liu H, Hu S, Miranda RN, Xu X, Bayerl MG, Artymiuk CJ, Berg H, King RL, Shi M, He R, Viswanatha D, Medeiros LJ, McPhail ED. Follicular lymphoma and diffuse large B-cell lymphoma with BCL2 and IRF4 rearrangements in adult patients. Hum Pathol. 2023 Nov; 141:22-29 Epub 2023 Aug 25
   View PubMed
8. Ravindran A, Dasari S, Ruan GJ, Artymiuk CJ, He R, Viswanatha DS, Abeykoon JP, Zanwar S, Young JR, Goyal G, Go RS, Rech KL, Mayo Clinic-The University of Alabama at Birmingham Histiocytosis Working Group. Malignant Histiocytosis Comprises a Phenotypic Spectrum That Parallels the Lineage Differentiation of Monocytes, Macrophages, Dendritic Cells, and Langerhans Cells. Mod Pathol. 2023 Oct; 36 (10):100268 Epub 2023 July 04
   View PubMed
9. Badar T, Vanegas YAM, Nanaa A, Foran JM, Al-Kali A, Mangaonkar A, Murthy H, Alkhateeb HB, Viswanatha D, He R, Shah M, Yi CA, Litzow MR, Gangat N, Tefferi A, Patnaik MM. U2AF1 pathogenic variants in myeloid neoplasms and precursor states: distribution of co-mutations and prognostic heterogeneity. Blood Cancer J. 2023 Sep 21; 13(1):149.
   View PubMed
10. Pitel BA, Zepeda-Mendoza C, Sachs Z, Tang H, Shivaram S, Sharma N, Smadbeck JB, Smoley SA, Pearce KE, Luoma IM, Cook J, Litzow MR, Hoppman NL, Viswanatha D, Xu X, Ketterling RP, Greipp PT, Peterson JF, Baughn LB. Prospective evaluation of genome sequencing to compare conventional cytogenetics in acute myeloid leukemia. Blood Cancer J 2023 Sep 6; 13 (1):138 Epub 2023 Sept 06
    View PubMed
11. Abdelmagid MG, Al-Kali A, Litzow MR, Begna KH, Hogan WJ, Patnaik MS, Hashmi SK, Elliott MA, Alkhateeb H, Karrar OS, Fleti F, Elnayir MH, Rivera CE, Murthy HS, Foran JM, Kharfan-Dabaja MA, Badar T, Viswanatha DS, Reichard KK, Gangat N, Tefferi A. Real-world experience with ponatinib therapy in chronic phase chronic myeloid leukemia: impact of depth of response on survival and prior exposure to nilotinib on arterial occlusive events. Blood Cancer J. 2023 Aug 11; 13 (1):122
    View PubMed
12. Gurney M, Mangaonkar AA, Lasho T, Finke C, Al-Kali A, Gangat N, Shah MV, Alkhateeb HB, Tefferi A, Sallman D, Xie Z, Viswanatha D, Reichard K, Al Ali N, Komrokji R, Padron E, Patnaik MM. Somatic TP53 single nucleotide variants, indels and copy number alterations in chronic myelomonocytic leukemia (CMML). Leukemia 2023 Aug; 37 (8):1753-1756 Epub 2023 July 08
    View PubMed
13. Balan J, Koganti T, Basu S, Dina MA, Artymiuk CJ, Barr Fritcher EG, Halverson KE, Wu X, Jenkinson G, Viswanatha DS. MICon Contamination Detection Workflow for Next-Generation Sequencing Laboratories Using Microhaplotype Loci and Supervised Learning. J Mol Diagn. 2023 Aug; 25 (8):602-610 Epub 2023 May 25
    View PubMed
14. Gutierrez-Rodrigues F, Kusne Y, Fernandez J, Lasho T, Shalhoub R, Ma X, Alessi H, Finke C, Koster MJ, Mangaonkar A, Warrington KJ, Begna K, Xie Z, Ombrello AK, Viswanatha D, Ferrada M, Wilson L, Go R, Kourelis T, Reichard K, Olteanu H, Darden I, Hironaka D, Alemu L, Kajigaya S, Rosenzweig S, Calado RT, Groarke EM, Kastner DL, Calvo KR, Wu CO, Grayson PC, Young NS, Beck DB, Patel BA, Patnaik MM. Spectrum of clonal hematopoiesis in VEXAS syndrome. Blood. 2023 Jul 20; 142 (3):244-259
    View PubMed
15. Gurney M, Chekkaf I, Baranwal A, Basmaci R, Katamesh B, Greipp P, Foran JM, Badar T, Mangaonkar AA, Begna KH, Gangat N, Patnaik MM, Litzow MR, Shah MV, Viswanatha DS, He R, Alkhateeb HB, Al-Kali A. The clinical and molecular spectrum of ETV6 mutated myeloid neoplasms. Br J Haematol. 2023 Jul; 202 (2):279-283 Epub 2023 May 05
    View PubMed
16. Katamesh B, Nanaa A, He R, Viswanatha D, Nguyen P, Greipp P, Bessonen K, Gangat N, Begna K, Mangaonkar A, Patnaik M, Hogan WJ, Tefferi A, Litzow M, Shah MV, Yi CA, Foran J, Badar T, Alkhateeb HB, Al-Kali A. Clinical and prognostic impact of STAG2 mutations in myeloid neoplasms: the Mayo Clinic experience. Blood Adv. 2023 Apr 25; 7 (8):1351-1355
    View PubMed
17. Al-Kali A, Nanaa A, Viswanatha D, He R, Nguyen P, Jevremovic D, Foran JM, Yi CA, Greipp PT, Gangat N, Patnaik M, Tefferi A, Litzow MR, Mangaonkar AA, Shah MV, Badar T, Alkhateeb HB. Observation and treatment in DDX41-mutated acute myeloid leukemia and myelodysplastic syndrome. Blood Cancer J 2023 Apr 10; 13 (1):49
    View PubMed
18. Pritzl SL, Gurney M, Badar T, Ferrer A, Lasho T, Finke C, Mangaonkar A, McCullough K, Gangat N, Fernandez J, Al-Kali A, Viswanatha D, He R, Foran J, Patnaik MM. Clinical and molecular spectrum and prognostic outcomes of U2AF1 mutant clonal hematopoiesis- a prospective mayo clinic cohort study. Leuk Res. 2023 Feb; 125:107007 Epub 2022 Dec 28
    View PubMed
19. Tefferi A, Singh A, Gangat N, Al-Kali A, Alkhateeb H, Shah M, Patnaik MS, Elliott MA, Hogan WJ, Litzow MR, Wolanskyj-Spinner A, Hook CC, Mangaonkar A, Viswanatha D, Chen D, Pardanani A, Begna KH, Ketterling RP. Adverse karyotype subcategories in acute myeloid leukemia display significant differences in mutation composition and transplant-augmented survival. Haematologica 2023 Jan 1; 108 (1):245-249 Epub 2023 Jan 01
    View PubMed
20. Katamesh B, Nanaa A, He R, Viswanatha D, Nguyen P, Greipp P, Foran J, Begna K, Gangat N, Patnaik M, Tefferi A, Litzow M, Mangaonkar A, Shah MV, Badar T, Alkhateeb HB, Al-Kali A. Co-mutational pattern of somatic GATA2-mutated myeloid neoplasms. Ann Hematol 2023 Jan; 102 (1):211-212 Epub 2022 Nov 04
    View PubMed
21. Balan J, Koganti T, Basu S, Dina MA, Artymiuk CJ, Barr Fritcher EG, Halverson KE, Wu X, Jenkinson G, Viswanatha DS. MICon contamination detection workflow for next-generation sequencing laboratories using microhaplotype loci and supervised learning. Journal of Molecular Diagnostics: JMD. 2023; 25 (8):602-10
    
22. Katamesh B, Nanaa A, He R, Viswanatha D, Nguyen P, Greipp P, Foran J, Begna K, Gangat N, Patnaik M, Tefferi A, Litzow M, Mangaonkar A, Shah MV, Badar T, Alkhateeb HB, Al-Kali A. Autoimmune manifestations in STAG2-mutated myeloid neoplasms. Ann Hematol 2022 Dec; 101 (12):2785-2787 Epub 2022 Oct 03
    View PubMed
23. Baranwal A, Nanaa A, Viswanatha D, He R, Foran J, Badar T, Hogan WJ, Litzow MR, Shah MV, Patnaik MM, Al-Kali A, Alkhateeb HB. Outcomes of allogeneic transplant in patients with DDX41 mutated myelodysplastic syndrome and acute myeloid leukemia. Bone Marrow Transplant 2022 Nov; 57 (11):1716-1718 Epub 2022 Aug 20
    View PubMed
24. Jevremovic D, Nanaa A, Geyer SM, Timm M, Azouz H, Hengel C, Reberg A, He R, Viswanatha D, Salama ME, Shi M, Olteanu H, Horna P, Otteson G, Greipp PT, Xie Z, Alkhateeb HB, Hogan W, Litzow M, Patnaik MM, Shah M, Al-Kali A, Nguyen PL. Abnormal CD13/HLA-DR Expression Pattern on Myeloblasts Predicts Development of Myeloid Neoplasia in Patients With Clonal Cytopenia of Undetermined Significance. Am J Clin Pathol. 2022 Oct 6; 158 (4):530-536
    View PubMed
25. Tefferi A, Gangat N, Shah M, Alkhateeb H, Patnaik MS, Al-Kali A, Elliott MA, Hogan WJ, Litzow MR, Hook CC, Mangaonkar A, Viswanatha D, Chen D, Pardanani A, Ketterling RP, Begna KH. Daunorubicin-60 versus daunorubicin-90 versus idarubicin-12 for induction chemotherapy in acute myeloid leukemia: a retrospective analysis of the Mayo Clinic experience. Haematologica. 2022 Oct 1; 107 (10):2474-2479 Epub 2022 Oct 01
    View PubMed
26. Nanaa A, He R, Viswanatha D, Nguyen P, Jevremovic D, Foran JM, Yi CA, Greipp PT, Gangat N, Patnaik M, Tefferi A, Litzow MR, Mangaonkar AA, Shah MV, Badar T, Alkhateeb HB, Al-Kali A. Comparison between GATA2 and DDX41-mutated myeloid neoplasms. Leuk Res 2022 Oct; 121:106931 Epub 2022 Aug 23
    View PubMed
27. Tefferi A, Gangat N, Al-Kali A, Alkhateeb H, Shah M, Patnaik MS, Elliott MA, Hogan WJ, Litzow MR, Hook CC, Mangaonkar A, Viswanatha D, Chen D, Pardanani A, Ketterling RP, DiNardo CD, Kadia TM, Ravandi F, Sasaki K, Begna KH. A dynamic 3-factor survival model for acute myeloid leukemia that accounts for response to induction chemotherapy. Am J Hematol. 2022 Sep; 97 (9):1127-1134 Epub 2022 June 30
    View PubMed
28. Zimmerman Zuckerman E, Thompson JA, Schneider AR, Campion MB, Johns JJ, Stier TJ, Peterson LM, Ward AM, Blommel JH, Gnanaolivu RD, Lauer KP, Sivasankaran G, Balan J, Dasari S, Sakai Y, Marcou CA, Zheng G, Halling KC, Shen W, Viswanatha DS, Niu Z. Automation of hybridization and capture based next generation sequencing library preparation requires reduction of on-deck bead binding and heated wash temperatures. SLAS Technol. 2022 Jun; 27 (3):214-218 Epub 2021 Nov 26
    View PubMed
29. Ng SWK, Murphy T, King I, Zhang T, Mah M, Lu Z, Stickle N, Ibrahimova N, Arruda A, Mitchell A, Mai M, He R, Madala BS, Viswanatha DS, Dick JE, Chan S, Virtanen C, Minden MD, Mercer T, Stockley T, Wang JCY. A clinical laboratory-developed LSC17 stemness score assay for rapid risk assessment of patients with acute myeloid leukemia. Blood Adv. 2022 Feb 8; 6 (3):1064-1073
    View PubMed
30. Alkhateeb HB, Nanaa A, Viswanatha D, Foran JM, Badar T, Sproat L, He R, Nguyen P, Jevremovic D, Salama ME, Greipp P, Gangat N, Tefferi A, Litzow MR, Mangaonkar AA, Shah MV, Patnaik M, Al-Kali A. Genetic features and clinical outcomes of patients with isolated and comutated DDX41-mutated myeloid neoplasms. Blood Adv. 2022 Jan 25; 6 (2):528-532
    View PubMed
31. He R, Chiou J, Chiou A, Chen D, Chen CP, Spethman C, Bessonen KR, Oliveira JL, Nguyen PL, Reichard KK, Hoyer JD, Althoff SD, Roh DJ, Miller MA, Yuan J, Olteanu H, Begna K, Tefferi A, Alkhateeb H, Patnaik MM, Litzow MR, Al-Kali A, Viswanatha DS. Molecular markers demonstrate diagnostic and prognostic value in the evaluation of myelodysplastic syndromes in cytopenia patients. Blood Cancer J 2022 Jan 25; 12 (1):12
    View PubMed
32. He R, Chiou J, Chiou A, Chen D, Chen CP, Spethman C, Bessonen KR, Oliveira JL, Nguyen PL, Reichard KK, Hoyer JD, Althoff SD, Roh DJ, Miller MA, Yuan J, Olteanu H, Begna K, Tefferi A, Alkhateeb H, Patnaik MM, Litzow MR, Al-Kali A, Viswanatha DS. Molecular markers demonstrate diagnostic and prognostic value in the evaluation of myelodysplastic syndromes in cytopenia patients. Blood Cancer J. 2022 Jan 25; 12(1):12.
    View PubMed
33. Jawad M, Afkhami M, Ding Y, Zhang X, Li P, Young K, Xu ML, Cui W, Zhao Y, Halene S, Al-Kali A, Viswanatha D, Chen D, He R, Zheng G. DNMT3A R882 Mutations Confer Unique Clinicopathologic Features in MDS Including a High Risk of AML Transformation. Front Oncol. 2022; 12:849376 Epub 2022 Feb 28
    View PubMed
34. Rangan A, Hein MS, Jenkinson WG, Koganti T, Aleff RA, Hilker CA, Blommel JH, Porter TR, Swanson KC, Lundquist P, Nguyen PL, Shi M, He R, Viswanatha DS, Jen J, Klee EW, Kipp BR, Hoyer JD, Wieben ED, Oliveira JL. Improved Characterization of Complex beta-Globin Gene Cluster Structural Variants Using Long-Read Sequencing. J Mol Diagn. 2021 Dec; 23 (12):1732-1740
    View PubMed
35. Martin ES, Ferrer A, Mangaonkar AA, Khan SP, Kohorst MA, Joshi AY, Hogan WJ, Olteanu H, Moyer AM, Al-Kali A, Tefferi A, Chen D, Wudhikarn K, Go R, Viswanatha D, He R, Ketterling R, Nguyen PL, Oliveira JL, Gangat N, Lasho T, Patnaik MM. Spectrum of hematological malignancies, clonal evolution and outcomes in 144 Mayo Clinic patients with germline predisposition syndromes. Am J Hematol. 2021 Nov 1; 96 (11):1450-1460 Epub 2021 Aug 27
    View PubMed
36. Venable ER, Chen D, Chen CP, Bessonen KR, Nguyen PL, Oliveira JL, Reichard KK, Hoyer JD, Althoff SD, Roh DJ, Miller MA, Begna K, Patnaik MM, Litzow MR, Al-Kali A, Viswanatha DS, He R. Pathologic Spectrum and Molecular Landscape of Myeloid Disorders Harboring SF3B1 Mutations. Am J Clin Pathol. 2021 Sep 8; 156 (4):679-690
    View PubMed
37. Mehta N, He R, Viswanatha DS. Internal Standardization of the Interpretation and Reporting of Sequence Variants in Hematologic Neoplasms. Mol Diagn Ther. 2021 Jul; 25 (4):517-526 Epub 2021 June 14
    View PubMed
38. Nanaa A, Viswanatha D, Xie Z, Jevremovic D, Nguyen P, Salama ME, Greipp P, Bessonen K, Gangat N, Patnaik M, Pardanani A, Alkhateeb HB, Shah M, Hogan W, Tefferi A, Litzow M, He R, Al-Kali A. Clinical and biological characteristics and prognostic impact of somatic GATA2 mutations in myeloid malignancies: a single institution experience. Blood Cancer J 2021 Jun 30; 11 (6):122 Epub 2021 June 30
    View PubMed
39. King RL, Siaghani PJ, Wong K, Edlefsen K, Shane L, Howard MT, Reichard KK, Mai M, Viswanatha DS, Greipp PT, Goble TA, Ruiz M, Hara H. Novel t(1;8)(p31.3;q21.3) NFIA-RUNX1T1 Translocation in an Infant Erythroblastic Sarcoma. Am J Clin Pathol. 2021 Jun 17; 156 (1):129-138
    View PubMed
40. Oishi N, Hundal T, Phillips JL, Dasari S, Hu G, Viswanatha DS, He R, Mai M, Jacobs HK, Ahmed NH, Syrbu SI, Salama Y, Chapman JR, Vega F, Sidhu J, Bennani NN, Epstein AL, Medeiros JL, Clemens MW, Miranda RN, Feldman AL. Molecular profiling reveals a hypoxia signature in breast implant-associated anaplastic large cell lymphoma. Haematologica. 2021 Jun 1; 106 (6):1714-1724 Epub 2021 June 01
    View PubMed
41. Begna KH, Ali W, Naseema Gangat Gangat, Elliott MA, Al-Kali A, Litzow MR, Christopher Hook C, Wolanskyj-Spinner AP, Hogan WJ, Patnaik MM, Pardanani A, Zblewski DL, Chen D, He R, Viswanatha D, Hanson CA, Ketterling RP, Tefferi A. Mayo Clinic experience with 1123 adults with acute myeloid leukemia. Blood Cancer J. 2021 Mar 2; 11 (3):46 Epub 2021 Mar 02
    View PubMed
42. Xie Z, Nanaa A, Saliba AN, He R, Viswanatha D, Nguyen P, Jevremovic D, Greipp P, Salama ME, Gangat N, Alkhateeb HB, Tefferi A, Litzow M, Patnaik M, Shah M, Al-Kali A. Treatment outcome of clonal cytopenias of undetermined significance: a single-institution retrospective study. Blood Cancer J 2021 Mar 1; 11 (3):43 Epub 2021 Mar 01
    View PubMed
43. Pitel BA, Sharma N, Zepeda-Mendoza C, Smadbeck JB, Pearce KE, Cook JM, Vasmatzis G, Sachs Z, Kanagal-Shamanna R, Viswanatha D, Xiao S, Jenkins RB, Xu X, Hoppman NL, Ketterling RP, Peterson JF, Greipp PT, Baughn LB. Myeloid malignancies with 5q and 7q deletions are associated with extreme genomic complexity, biallelic TP53 variants, and very poor prognosis. Blood Cancer J. 2021 Feb 8; 11(2):18.
    View PubMed
44. Pitel BA, Sharma N, Zepeda-Mendoza C, Smadbeck JB, Pearce KE, Cook JM, Vasmatzis G, Sachs Z, Kanagal-Shamanna R, Viswanatha D, Xiao S, Jenkins RB, Xu X, Hoppman NL, Ketterling RP, Peterson JF, Greipp PT, Baughn LB. Myeloid malignancies with 5q and 7q deletions are associated with extreme genomic complexity, biallelic TP53 variants, and very poor prognosis. Blood Cancer J 2021 Feb 8; 11 (2):18 Epub 2021 Feb 08
    View PubMed
45. Berg HE, Blackburn PR, Baughn LB, Ketterling RP, Xu X, Greipp PT, Hoppman NL, Smadbeck JB, Vasmatzis G, Shi M, Reichard KK, Viswanatha DS, Jevremovic D, Maher GM, Peterson JF. Identification of a novel KMT2A/GIMAP8 gene fusion in a pediatric patient with acute undifferentiated leukemia. Genes Chromosomes Cancer. 2021 Feb; 60 (2):108-111 Epub 2020 Oct 21
    View PubMed
46. Sadighi Akha AA, Tschumper RC, Mills JR, Isham CR, Witty EE, Viswanatha DS, Dasari S, Snyder MR, Murray DL, Katzmann JA, Jelinek DF, Willrich MAV. A rare case of selective Igkappa chain deficiency: Biologic and clinical implications. J Allergy Clin Immunol 2020 Nov; 146 (5):1208-1210.e6 Epub 2020 Apr 08
    View PubMed
47. Shi M, Olteanu H, Jevremovic D, He R, Viswanatha D, Corley H, Horna P. T-cell clones of uncertain significance are highly prevalent and show close resemblance to T-cell large granular lymphocytic leukemia. Implications for laboratory diagnostics. Mod Pathol. 2020 Oct; 33 (10):2046-2057 Epub 2020 May 13
    View PubMed
48. DiFilippo EC, Coltro G, Carr RM, Mangaonkar AA, Binder M, Khan SP, Rodriguez V, Gangat N, Wolanskyj A, Pruthi RK, Chen D, He R, Viswanatha DS, Lasho T, Finke C, Tefferi A, Pardanani A, Patnaik MM. Spectrum of abnormalities and clonal transformation in germline RUNX1 familial platelet disorder and a genomic comparative analysis with somatic RUNX1 mutations in MDS/MPN overlap neoplasms. Leukemia 2020 Sep; 34 (9):2519-2524 Epub 2020 Feb 14
    View PubMed
49. Joshi M, Greipp P, Ball C, Vinod Shah M, Khurana A, Yogarajah M, Nguyen P, He R, Viswanatha D, Jevremovic D, Salama M, Alkhateeb HB, Gangat N, Patnaik M, Begna K, Hogan W, Zblewski D, Litzow M, Al-Kali A. Characteristics of patients with myelodysplastic syndrome with balanced translocations. Br J Haematol. 2020 Jul; 190 (2):244-248 Epub 2020 Mar 17
    View PubMed
50. Fang H, He R, Chiu A, Viswanatha DS, Ketterling RP, Patnaik MS, Reichard KK. Genetic Factors in Acute Myeloid Leukemia With Myelodysplasia-Related Changes. Am J Clin Pathol. 2020 Apr 15; 153 (5):656-663
    View PubMed
51. He R, Devine DJ, Tu ZJ, Mai M, Chen D, Nguyen PL, Oliveira JL, Hoyer JD, Reichard KK, Ollila PL, Al-Kali A, Tefferi A, Begna KH, Patnaik MM, Alkhateeb H, Viswanatha DS. Correction to: Hybridization capture-based next-generation sequencing reliably detects FLT3 mutations and classifies FLT3-internal tandem duplication allelic ratio in acute myeloid leukemia: a comparative study to standard fragment analysis. Mod Pathol. 2020 Mar; 33 (3):514
    View PubMed
52. He R, Devine DJ, Tu ZJ, Mai M, Chen D, Nguyen PL, Oliveira JL, Hoyer JD, Reichard KK, Ollila PL, Al-Kali A, Tefferi A, Begna KH, Patnaik MM, Alkhateeb H, Viswanatha DS. Hybridization capture-based next generation sequencing reliably detects FLT3 mutations and classifies FLT3-internal tandem duplication allelic ratio in acute myeloid leukemia: a comparative study to standard fragment analysis. Mod Pathol. 2020 Mar; 33 (3):334-343 Epub 2019 Aug 30
    View PubMed
53. Ravindran A, He R, Ketterling RP, Jawad MD, Chen D, Oliveira JL, Nguyen PL, Viswanatha DS, Reichard KK, Hoyer JD, Go RS, Shi M. The significance of genetic mutations and their prognostic impact on patients with incidental finding of isolated del(20q) in bone marrow without morphologic evidence of a myeloid neoplasm. Blood Cancer J. 2020 Jan 23; 10 (1):7
    View PubMed
54. Gupta SK, Viswanatha DS, Patel KP. Evaluation of Somatic Hypermutation Status in Chronic Lymphocytic Leukemia (CLL) in the Era of Next Generation Sequencing. Front Cell Dev Biol. 2020; 8:357 Epub 2020 May 19
    View PubMed
55. Misund K, Keane N, Stein CK, Asmann YW, Day G, Welsh S, Van Wier SA, Riggs DL, Ahmann G, Chesi M, Viswanatha DS, Kumar SK, Dispenzieri A, Gonzalez-Calle V, Kyle RA, O'Dwyer M, Rajkumar SV, Kortum KM, Keats JJ, Fonseca R, Stewart AK, Kuehl WM, Braggio E, Bergsagel PL, MMRF CoMMpass Network. MYC dysregulation in the progression of multiple myeloma. Leukemia 2020 Jan; 34 (1):322-326 Epub 2019 Aug 22
    View PubMed
56. Peterson JF, Baughn LB, Ketterling RP, Pitel BA, Smoley SA, Vasmatzis G, Smadbeck JB, Greipp PT, Mangaonkar AA, Thompson CA, Parikh SA, Chen D, Viswanatha DS. Characterization of a cryptic IGH/CCND1 rearrangement in a case of mantle cell lymphoma with negative CCND1 FISH studies. Blood Adv. 2019 Apr 23; 3 (8):1298-1302
    View PubMed
57. Miller KC, Al-Kali A, Shah MV, Hogan WJ, Elliott MA, Begna KH, Gangat N, Patnaik MM, Viswanatha DS, He R, Greipp PT, Sproat LZ, Foran JM, Litzow MR, Alkhateeb HB. Elderly acute lymphoblastic leukemia: a Mayo Clinic study of 124 patients. Leuk Lymphoma. 2019 Apr; 60 (4):990-999 Epub 2018 Oct 02
    View PubMed
58. Sidiqi MH, Aljama MA, Viswanatha DS, Dingli D. T-cell large granular lymphocytic leukemia and plasma cell disorders. Haematologica 2019 Mar; 104 (3):e108-e110 Epub 2018 Sept 20
    View PubMed
59. Peterson JF, Rowsey RA, Marcou CA, Pearce KE, Williamson CM, Frederick LA, Greipp PT, Ketterling RP, Kumar S, Viswanatha DS, Polley MY, Fink JM, Reichard KK, Van Dyke DL, Baughn LB. Hyperhaploid plasma cell myeloma characterized by poor outcome and monosomy 17 with frequently co-occurring TP53 mutations. Blood Cancer J 2019 Feb 19; 9 (3):20
    View PubMed
60. Begna KH, Ali W, Gangat N, Elliott MA, Al-Kali A, Litzow MR, Hook CC, Wolanskyj AP, Hogan WJ, Patnaik MM, Pardanani A, Zblewski DL, Chen D, He R, Viswanatha D, Hanson CA, Ketterling RP, Tefferi A. A novel predictive model of outcome in acute myeloid leukemia without favorable karyotype based on treatment strategy, karyotype and FLT3-ITD mutational status. Am J Hematol 2018 Dec; 93 (12):E401-E404 Epub 2018 Oct 17
    View PubMed
61. Alkharabsheh O, Al-Kali A, Saadeh S, He R, Viswanatha D, Greipp P, Reichard K, Shah M, Gangat N, Patnaik M, Hogan W, Litzow M, Alkhateeb H, Nguyen PL. The clinical outcomes of reclassified erythroleukemia (erythroid/myeloid) as myelodysplastic syndrome (MDS) per 2017 WHO guideline compared to MDS. Am J Hematol 2018 Nov; 93 (11):E355-E357 Epub 2018 Oct 02
    View PubMed
62. Tefferi A, Gangat N, Mudireddy M, Lasho TL, Finke C, Begna KH, Elliott MA, Al-Kali A, Litzow MR, Hook CC, Wolanskyj AP, Hogan WJ, Patnaik MM, Pardanani A, Zblewski DL, He R, Viswanatha D, Hanson CA, Ketterling RP, Tang JL, Chou WC, Lin CC, Tsai CH, Tien HF, Hou HA. Mayo Alliance Prognostic Model for Myelodysplastic Syndromes: Integration of Genetic and Clinical Information. Mayo Clin Proc. 2018 Oct; 93 (10):1363-1374 Epub 2018 June 14
    View PubMed
63. Higgins A, Mangaonkar AA, Hefazi M, Viswanatha D, Horna P, Foran J, Gangat N. Non-internal tandem duplication (ITD), non-tyrosine kinase domain (TKD) FLT3 mutations in myeloid malignancies: A brief report of 10 patients. Leuk Res 2018 Sep; 72:1-4 Epub 2018 July 21
    View PubMed
64. Oishi N, Brody GS, Ketterling RP, Viswanatha DS, He R, Dasari S, Mai M, Benson HK, Sattler CA, Boddicker RL, McPhail ED, Bennani NN, Harless CA, Singh K, Clemens MW, Medeiros LJ, Miranda RN, Feldman AL. Genetic subtyping of breast implant-associated anaplastic large cell lymphoma. Blood 2018 Aug 2; 132 (5):544-547 Epub 2018 June 19
    View PubMed
65. Fang H, Kapoor P, Gonsalves WI, Frederick LA, Viswanatha D, Howard MT, He R, Morice WG 2nd, McPhail ED, Greipp PT, Ansell SM, Kyle RA, Gertz MA, Paludo J, Abeykoon J, King RL. Defining Lymphoplasmacytic Lymphoma: Does MYD88L265P Define a Pathologically Distinct Entity Among Patients With an IgM Paraprotein and Bone Marrow-Based Low-Grade B-Cell Lymphomas With Plasmacytic Differentiation? Am J Clin Pathol. 2018 Jul 3; 150 (2):168-176
    View PubMed
66. Perez Botero J, Ho TP, Hogan WJ, Kenderian S, Gangat N, Tefferi A, Abraham RS, Nguyen P, Oliveira JL, He R, Chen D, Viswanatha D, Rodriguez V, Khan SP, Patnaik MM. Clinical spectrum and clonal evolution in germline syndromes with predisposition to myeloid neoplasms. Br J Haematol. 2018 Jul; 182 (1):141-145 Epub 2017 May 09
    View PubMed
67. He R, Ding W, Viswanatha DS, Chen D, Shi M, Van Dyke D, Tian S, Dao LN, Parikh SA, Shanafelt TD, Call TG, Ansell SM, Leis JF, Mai M, Hanson CA, Rech KL. PD-1 Expression in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Large B-cell Richter Transformation (DLBCL-RT): A Characteristic Feature of DLBCL-RT and Potential Surrogate Marker for Clonal Relatedness. Am J Surg Pathol. 2018 Jul; 42 (7):843-854
    View PubMed
68. Oliveira JL, Coon LM, Frederick LA, Hein M, Swanson KC, Savedra ME, Porter TR, Patnaik MM, Tefferi A, Pardanani A, Grebe SK, Viswanatha DS, Hoyer JD. Genotype-Phenotype Correlation of Hereditary Erythrocytosis Mutations, a single center experience. Am J Hematol. 2018 May 23 [Epub ahead of print]
    View PubMed
69. Shi M, He R, Feldman AL, Viswanatha DS, Jevremovic D, Chen D, Morice WG. STAT3 mutation and its clinical and histopathologic correlation in T-cell large granular lymphocytic leukemia. Hum Pathol. 2018 Mar; 73:74-81 Epub 2017 Dec 27
    View PubMed
70. Abeykoon JP, Paludo J, King RL, Ansell SM, Gertz MA, LaPlant BR, Halvorson AE, Gonsalves WI, Dingli D, Fang H, Rajkumar SV, Lacy MQ, He R, Kourelis T, Reeder CB, Novak AJ, McPhail ED, Viswanatha DS, Witzig TE, Go RS, Habermann TM, Buadi FK, Dispenzieri A, Leung N, Lin Y, Thompson CA, Hayman SR, Kyle RA, Kumar SK, Kapoor P. MYD88 mutation status does not impact overall survival in Waldenstrom macroglobulinemia. Am J Hematol. 2018 Feb; 93 (2):187-194 Epub 2017 Nov 17
    View PubMed
71. Gupta A, Viswanatha DS, Patnaik MM. FLT3 Mutation Testing in Acute Myeloid Leukemia. JAMA Oncol. 2017 Jul 1; 3 (7):991-992
    View PubMed
72. Ding W, LaPlant BR, Call TG, Parikh SA, Leis JF, He R, Shanafelt TD, Sinha S, Le-Rademacher J, Feldman AL, Habermann TM, Witzig TE, Wiseman GA, Lin Y, Asmus E, Nowakowski GS, Conte MJ, Bowen DA, Aitken CN, Van Dyke DL, Greipp PT, Liu X, Wu X, Zhang H, Secreto CR, Tian S, Braggio E, Wellik LE, Micallef I, Viswanatha DS, Yan H, Chanan-Khan AA, Kay NE, Dong H, Ansell SM. Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. Blood. 2017 Jun 29; 129 (26):3419-3427 Epub 2017 Apr 19
    View PubMed
73. Perez Botero J, Chen D, He R, Viswanatha DS, Majerus JA, Coon LM, Nguyen PL, Reichard KK, Oliveira JL, Tefferi A, Gangat N, Pruthi RK, Patnaik MM. Clinical and laboratory characteristics in congenital ANKRD26 mutation-associated thrombocytopenia: A detailed phenotypic study of a family. Platelets. 2016 Nov; 27 (7):712-715 Epub 2016 Apr 28
    View PubMed
74. King RL, Gonsalves WI, Ansell SM, Greipp PT, Frederick LA, Viswanatha DS, He R, Kyle RA, Gertz MA, Kapoor P, Morice WG, Howard MT. Lymphoplasmacytic Lymphoma With a Non-IgM Paraprotein Shows Clinical and Pathologic Heterogeneity and May Harbor MYD88 L265P Mutations. Am J Clin Pathol. 2016 Jun; 145 (6):843-51 Epub 2016 June 21
    View PubMed
75. He R, Greipp PT, Rangan A, Mai M, Chen D, Reichard KK, Nelsen LL, Pardanani A, Hanson CA, Viswanatha DS. BCR-JAK2 fusion in a myeloproliferative neoplasm with associated eosinophilia. Cancer Genet. 2016 May; 209: (5)223-8.
    View PubMed
76. Pulido JS, Raja H, Vile RG, Salomao DR, Viswanatha DS. Mighty MyD88 in Health and Disease. Retina 2016 Mar; 36 (3):429-31
    View PubMed
77. Raja H, Salomao DR, Viswanatha DS, Pulido JS. PREVALENCE OF MYD88 L265P MUTATION IN HISTOLOGICALLY PROVEN, DIFFUSE LARGE B-CELL VITREORETINAL LYMPHOMA. Retina. 2016 Mar; 36 (3):624-8
    View PubMed
78. Kortuem KM, Braggio E, Bruins L, Barrio S, Shi CS, Zhu YX, Tibes R, Viswanatha D, Votruba P, Ahmann G, Fonseca R, Jedlowski P, Schlam I, Kumar S, Bergsagel PL, Stewart AK. Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients. Blood Cancer J. 2016 Feb 26; 6:e397
    View PubMed
79. Perez Botero J, Oliveira JL, Chen D, Chen D, Reichard KK, Viswanatha DS, Nguyen PL, Pruthi RK, Majerus J, Gada P, Gangat N, Tefferi A, Patnaik MM. ASXL1 mutated chronic myelomonocytic leukemia in a patient with familial thrombocytopenia secondary to germline mutation in ANKRD26. Blood Cancer J 2015 May 22; 5:e315
    View PubMed
80. Pulido JS, Salomao DR, Frederick LA, Viswanatha DS. MyD-88 L265P mutations are present in some cases of vitreoretinal lymphoma. Retina. 2015 Apr; 35 (4):624-7
    View PubMed
81. Bowen DA, Rabe KG, Schwager SM, Slager SL, Call TG, Viswanatha DS, Zent CS. Infectious lymphadenitis in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma: A rare, but important, complication. Leuk Lymphoma. 2015; 56(2):311-4.
    View PubMed
82. He R, Hanson CA, Chen D, Oliveira JL, Pardanani A, Reichard KK, Viswanatha DS. Not all CALR mutations are created equal. Leuk Lymphoma 2015; 56 (8):2482-3 Epub 2015 Aug 17
    View PubMed
83. Conte MJ, Bowen DA, Wiseman GA, Rabe KG, Slager SL, Schwager SM, Call TG, Viswanatha DS, Zent CS. Use of positron emission tomography-computed tomography in the management of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Leuk Lymphoma. 2014 Sep; 55 (9):2079-84 Epub 2014 Feb 17
    View PubMed
84. Jevremovic D, Timm MM, Reichard KK, Morice WG, Hanson CA, Viswanatha DS, Howard MT, Nguyen PL. Loss of blast heterogeneity in myelodysplastic syndrome and other chronic myeloid neoplasms. Am J Clin Pathol. 2014 Sep; 142(3):292-8.
    View PubMed
85. Frederick L, Beardell F, Viswanatha DS. Novel BCR-ABL1 fusion identified by targeted next-generation sequencing in a patient with an atypical myeloproliferative neoplasm. Hum Pathol. 2014 Aug; 45(8):1784-9. Epub 2014 May 08.
    View PubMed
86. Zent CS, Taylor RP, Lindorfer MA, Beum PV, LaPlant B, Wu W, Call TG, Bowen DA, Conte MJ, Frederick LA, Link BK, Blackwell SE, Veeramani S, Baig NA, Viswanatha DS, Weiner GJ, Witzig TE. Chemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cells. Am J Hematol. 2014 Jul; 89 (7):757-65 Epub 2014 Apr 26
    View PubMed
87. Wang X, Bledsoe KL, Graham RP, Asmann YW, Viswanatha DS, Lewis JE, Lewis JT, Chou MM, Yaszemski MJ, Jen J, Westendorf JJ, Oliveira AM. Recurrent PAX3-MAML3 fusion in biphenotypic sinonasal sarcoma. Nat Genet. 2014 Jul; 46 (7):666-8 Epub 2014 May 25
    View PubMed
88. Greipp PT, Smoley SA, Viswanatha DS, Frederick LS, Rabe KG, Sharma RG, Slager SL, Van Dyke DL, Shanafelt TD, Tschumper RC, Zent CS. Patients with chronic lymphocytic leukaemia and clonal deletion of both 17p13.1 and 11q22.3 have a very poor prognosis. Br J Haematol. 2013 Nov; 163(3):326-33. Epub 2013 Aug 27.
    View PubMed
89. Endly DC, Weenig RH, Peters MS, Viswanatha DS, Comfere NI. Indolent course of cutaneous gamma-delta T-cell lymphoma. J Cutan Pathol. 2013 Oct; 40(10):896-902. Epub 2013 Feb 04.
    View PubMed
90. West DS, Dogan A, Quint PS, Tricker-Klar ML, Porcher JC, Ketterling RP, Law ME, McPhail ED, Viswanatha DS, Kurtin PJ, Dao LN, Ritzer RD, Nowakowski GS, Feldman AL. Clonally related follicular lymphomas and Langerhans cell neoplasms: expanding the spectrum of transdifferentiation. Am J Surg Pathol. 2013 Jul; 37(7):978-86.
    View PubMed
91. He R, Viswanatha DS. Leukemic phase of ALK-positive anaplastic large cell lymphoma. Blood. 2013 Mar 14; 121 (11):1934
    View PubMed
92. Chen D, Bachanova V, Ketterling RP, Begna KH, Hanson CA, Viswanatha DS. A case of nonleukemic myeloid sarcoma with FIP1L1-PDGFRA rearrangement: an unusual presentation of a rare disease. Am J Surg Pathol. 2013 Jan; 37: (1)147-51.
    View PubMed
93. Vasmatzis G, Johnson SH, Knudson RA, Ketterling RP, Braggio E, Fonseca R, Viswanatha DS, Law ME, Kip NS, Ozsan N, Grebe SK, Frederick LA, Eckloff BW, Thompson EA, Kadin ME, Milosevic D, Porcher JC, Asmann YW, Smith DI, Kovtun IV, Ansell SM, Dogan A, Feldman AL. Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas. Blood. 2012 Sep 13; 120 (11):2280-9 Epub 2012 Aug 01
    View PubMed
94. Smeltzer JP, Viswanatha DS, Habermann TM, Patnaik MM. Secondary Epstein-Barr virus associated lymphoproliferative disorder developing in a patient with angioimmunoblastic T cell lymphoma on vorinostat. Am J Hematol. 2012 Sep; 87 (9):927-8 Epub 2012 June 20
    View PubMed
95. Raza S, Viswanatha D, Frederick L, Lasho T, Finke C, Knudson R, Ketterling R, Pardanani A, Tefferi A. TP53 mutations and polymorphisms in primary myelofibrosis. Am J Hematol. 2012 Feb; 87(2):204-6. Epub 2011 Nov 4.
    View PubMed
96. Chen D, Ketterling RP, Hanson CA, Colgan JP, Zent CS, Viswanatha DS. A case of hairy cell leukemia with CCND1-IGH@ translocation: indolent non-nodal mantle cell lymphoma revisited. Am J Surg Pathol. 2011 Jul; 35(7):1080-4.
    View PubMed
97. Jevremovic D, Viswanatha DS. Molecular diagnosis of hematopoietic and lymphoid neoplasms. Hematol Oncol Clin North Am. 2009 Aug; 23(4):903-33.
    View PubMed
98. Jones D, Kamel-Reid S, Bahler D, Dong H, Elenitoba-Johnson K, Press R, Quigley N, Rothberg P, Sabath D, Viswanatha D, Weck K, Zehnder J. Laboratory practice guidelines for detecting and reporting BCR-ABL drug resistance mutations in chronic myelogenous leukemia and acute lymphoblastic leukemia: a report of the Association for Molecular Pathology. J Mol Diagn. 2009 Jan; 11 (1):4-11 Epub 2008 Dec 18
    View PubMed
99. Borowitz MJ, Devidas M, Hunger SP, Bowman WP, Carroll AJ, Carroll WL, Linda S, Martin PL, Pullen DJ, Viswanatha D, Willman CL, Winick N, Camitta BM, Children's Oncology Group. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood. 2008 Jun 15; 111(12):5477-85. Epub 2008 Apr 03.
    View PubMed
100. Hanson CA, Steensma DP, Hodnefield JM, Nguyen PL, Hoyer JD, Viswanatha DS, Zou Y, Knudson RA, Van Dyke DL, Ketterling RP. Isolated trisomy 15: a clonal chromosome abnormality in bone marrow with doubtful hematologic significance. Am J Clin Pathol. 2008 Mar; 129(3):478-85.
     View PubMed
101. Viswanatha DS, Dogan A. Hepatitis C virus and lymphoma. J Clin Pathol. 2007 Dec; 60 (12):1378-83
     View PubMed
102. Hayani A, Lampeter E, Viswanatha D, Morgan D, Salvi SN. First report of autologous cord blood transplantation in the treatment of a child with leukemia. Pediatrics. 2007 Jan; 119(1):E296-E300.
     View PubMed
103. Chen IM, Chakerian A, Devidas M, Borowitz MJ, Hunger SP, Willman CL, Viswanatha DS. Resolution of ambiguous low-level positive quantitative polymerase chain reaction results in TEL-AML1 positive ALL using a post-PCR fluorescent oligoligation method. Br J Haematol. 2006 Nov; 135(3):358-61. Epub 2006 Sep 19.
     View PubMed
104. Starkey CR, Corn AI, Porensky RS, Viswanatha D, Wilson CS. Peripheral T-cell lymphoma with extensive dendritic cell network mimicking follicular dendritic cell tumor: a case report with pathologic, immunophenotypic, and molecular findings. Am J Clin Pathol. 2006 Aug; 126(2):230-4.
     View PubMed
105. Merchant SH, Amin MB, Viswanatha DS. Morphologic and immunophenotypic analysis of angioimmunoblastic T-cell lymphoma: Emphasis on phenotypic aberrancies for early diagnosis. Am J Clin Pathol. 2006 Jul; 126(1):29-38.
     View PubMed
106. Reichard KK, Zhang QY, Sanchez L, Hozier J, Viswanatha D, Foucar K. Acute myeloid leukemia of donor origin after allogeneic bone marrow transplantation for precursor T-cell acute lymphoblastic leukemia: case report and review of the literature. Am J Hematol. 2006 Mar; 81(3):178-85.
     View PubMed
107. Reichard KK, Burks EJ, Foucar MK, Wilson CS, Viswanatha DS, Hozier JC, Larson RS. CD4(+) CD56(+) lineage-negative malignancies are rare tumors of plasmacytoid dendritic cells. Am J Surg Pathol. 2005 Oct; 29(10):1274-83.
     View PubMed
108. Merchant SH, Amin MB, Viswanatha DS, Malhotra RK, Moehlenkamp C, Joste NE. p57KIP2 immunohistochemistry in early molar pregnancies: emphasis on its complementary role in the differential diagnosis of hydropic abortuses. Human Pathology. 2005; 36:180-186.
     View PubMed
109. Pai RK, Chakerian AE, Binder JM, Amin M, Viswanatha DS. B-cell clonality determination using an immunoglobulin kappa light chain polymerase chain reaction method. J Mol Diagn. 2005; 7:300-307.
     View PubMed
110. Pai RK, Snider WK, Starkey CR, Viswanatha D, Foucar MK, Wilson CS. Nonsecretory variant of immunoproliferative small intestinal disease: a case report with pathologic, immunophenotypic, and molecular findings. Arch Pathol Lab Med. 2005; 129(11):1487-90.
     View PubMed
111. Chen I-M, Chakerian A, Combs D, Garner K, Viswanatha DS. Post-PCR multiplex fluorescent ligation detection assay and flow cytometry for rapid detection of gene-specific translocations in leukemia. Am J Clin Pathol. 2004; 122:783-793.
     View PubMed
112. Merchant SH, Haines S, Hall B, Hozier J, Viswanatha DS. Fluorescence in-situ hybridization identifies cryptic t(16;16)(p13;q22) masked by del(q22) in a case of AML-M4Eo. J Mol Diagn. 2004; 6:271-274.
     View PubMed
113. Borowitz MJ, Pullen DJ, Shuster JJ, Viswanatha D, Montgomery K, Willman CL, Camitta B. Minimal residual disease detection in childhood precursor B-cell acute lymphoblastic leukemia: relation to other risk factors. A Children's Oncology Group Study Leukemia. 2003; 17:1566-1572.
     
114. Fischer EG, Bocklage TJ, Rabinowitz I, Smith HO, Viswanatha DS. Primary plasmacytoma arising in an endocervical polyp with eetection of neoplastic cells on the Pap smear: report of a case and review of the literature. Arch Path Lab Med. 2003; 127:e28-e31.
     View PubMed
115. Gaffney R, Chakerian A, O’Connell JX, Mathers J, Joste N, Viswanatha DS. Novel fluorescent ligase detection assay identifies SYT-SSX fusion type in synovial sarcoma. J Mol Diagn. 2003; 5:127-135.
     View PubMed
116. Merchant SH, Viswanatha DS, Zumwalt RE, Foucar K. Epstein-Bar virus-associated intravascular large T-cell lymphoma presenting as acute renal failure in a patient with acquired immune deficiency syndrome. Hum Pathol. 2003; 34:950-954.
     View PubMed
117. Viswanatha DS, Foucar K. Hodgkin and non-Hodgkin lymphoma involving bone marrow. Sem Diagn Pathol. 2003; 20(3):196-210.
     
118. Zhang Q-Y, Garner K, Viswanatha DS. Rapid detection of leukemia-associated translocation fusion genes using a novel combined RT-PCR and flow cytometric method. Leukemia. 2002; 16:144-149.
     View PubMed
119. Bartolo C, Viswanatha DS. Molecular methods for minimal residual disease detection in hematolymphoid diseases: principles and applications. J Clin Ligand Assay. 2001; 24(2):76-93.
     
120. Slack JL, Willman CL, Andersen JW, Li YP, Viswanatha DS, Bloomfield CD, Tallman MS, Gallagher RE. Molecular analysis and clinical outcome of adult APL patients with the type V PML-RARalpha isoform: results from intergroup protocol 0129. Blood. 2000 Jan 15; 95(2):398-403.
     View PubMed
121. Au W, Horsman DE, Viswanatha DS, Connors JM, Klasa RJ, Gascoyne RD. 8q24 translocations in blastic transformation of mantle cell lymphoma. Haematologica. 2000; 85(11):1225-1227.
     View PubMed
122. Beaubier NT, Hart AP, Bartolo C, Willman CL, Viswanatha DS. Comparison of capillary electrophoresis and polyacrylamide gel electrophoresis for the evaluation of T and B cell clonality by polymerase chain reaction. Diagn Mol Pathol. 2000; 9(3):121-131.
     View PubMed
123. Chao A, Gilliland F, Willman C, Joste N, Chen I, Stone N, Ruschulte J, Viswanatha D, Duncan P, Ming R, Hoffman R, Foucar E, Key C. Patient and tumor characteristics of colon cancers with microsatellite instability: a population-based study. Cancer Epidemiol Biomark Prev. 2000; 9:539-544.
     
124. Evans HL, Burks E, Viswanatha D, Larson RS. Utility of immunohistochemistry in bone marrow evaluation of T-lineage large granular lymphocyte leukemia. Hum Pathol. 2000; 31(10):1266-73.
     View PubMed
125. Viswanatha DS, Foucar K, Berry B, Gascoyne RD, Evans HL, Leith CP. Blastic mantle cell leukemia: an unusual presentation of blastic mantle cell lymphoma. Mod Pathol. 2000; 13(7):823-832.
     View PubMed
126. Au WY, Gascoyne RD, Le N, Viswanatha DS, Klasa RJ, Gallagher R, Connors JM. Incidence of second neoplasms in patients with MALT lymphoma: no increase in risk above the background population. Ann Oncol. 1999; 10:317-321.
     View PubMed
127. Au WY, Gascoyne RD, Viswanatha DS, Skinnider BF, Connors JM, Klasa RJ, Horsman DE. Concurrent Chromosomal Alterations at 3q27, 8q24 and 18q21 in B-cell Lymphomas. Br J Haematol. 1999; 105(2):437-440.
     View PubMed
128. Finn LS, Viswanatha DS, Belasco JB, Snyder H, Huebner D, Sorbara L, Raffeld M, Jaffe ES, Salhany KE. Primary follicular lymphoma of the testis in childhood. Cancer. 1999; 85(7):1626-1635.
     View PubMed
129. Gascoyne RD, Aoun P, Wu D, Chhanabhai M, Skinnider BF, Greiner TC, Morris SW, Connors JM, Vose JM, Viswanatha DS, Coldman A, Weisenburger DD. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood. 1999; 93(11):3913-3921.
     View PubMed
130. Skinnider BF, Clement PB, MacPherson N, Gascoyne RD, Viswanatha DS. Primary non-Hodgkin's lymphoma and malakoplakia of the vagina: a case report. Hum Pathol. 1999; 30(7):871-874.
     View PubMed
131. Rimsza LM, Viswanatha DS, Winter SS, Leith CP, Frost JD, Foucar K. The presence of CD34+ cell clusters predicts impending relapse in children with acute lymphoblastic leukemia receiving maintenance chemotherapy. Am J Clin Pathol. 1998 Sep; 110(3):313-20.
     View PubMed
132. Viswanatha DS, Chen IM, Liu PP, Slovak ML, Rankin C, Head DR, Willman CL. Characterization and use of an antibody detecting the CBFB/SM MHC fusion protein in inv 16/t(16;16)-associated acute myeloid leukemias. Blood. 1998; 91(6):1882-1890.
     View PubMed
133. Gallagher RE, Willman CL, Slack J, Andersen J, Li Y-P, Viswanatha DS, Bloomfield CD, Appelbaum FR, Schiffer CA, Tallman MS, Wiernik P. Association of PML-RARA fusion mRNA type with pretreatment hematologic characteristics but not treatment outcome in acute promyelocytic leukemia: an intergroup molecular study. Blood. 1997; 90(4):1656-1663.
     View PubMed
134. Shum DT, Guenther L, Viswanatha D. Usefulness of the dissecting microscope in the surgical management of skin cancers. J Derm Surg Onc. 1994; 20(4):266-271.